Morgan Stanley’s Applied Therapeutics APLT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-178,474
| Closed | -$17.8K | – | 8296 |
|
|
2025
Q4 | $17.8K | Sell |
178,474
-534,841
| -75% | -$340K | ﹤0.01% | 6729 |
|
|
2025
Q3 | $431K | Buy |
713,315
+370,679
| +108% | +$175K | ﹤0.01% | 5564 |
|
|
2025
Q2 | $107K | Sell |
342,636
-2,529,588
| -88% | -$979K | ﹤0.01% | 6105 |
|
|
2025
Q1 | $1.4M | Sell |
2,872,224
-5,943,556
| -67% | -$3.5M | ﹤0.01% | 4821 |
|
|
2024
Q4 | $7.55M | Sell |
8,815,780
-1,088,750
| -11% | -$6.82M | ﹤0.01% | 3632 |
|
|
2024
Q3 | $84.2M | Buy |
9,904,530
+6,384,793
| +181% | +$37.6M | 0.01% | 1379 |
|
|
2024
Q2 | $16.4M | Buy |
3,519,737
+325,685
| +10% | +$1.54M | ﹤0.01% | 2878 |
|
|
2024
Q1 | $21.7M | Buy |
3,194,052
+3,086,806
| +2,878% | +$13.9M | ﹤0.01% | 2605 |
|
|
2023
Q4 | $359K | Buy |
107,246
+55,875
| +109% | +$139K | ﹤0.01% | 5742 |
|
|
2023
Q3 | $128K | Sell |
51,371
-3,353
| -6% | -$5.53K | ﹤0.01% | 5766 |
|
|
2023
Q2 | $70K | Buy |
54,724
+54,528
| +27,820% | +$72.3K | ﹤0.01% | 6086 |
|
|
2023
Q1 | $159 | Sell |
196
-4,284
| -96% | -$4.22K | ﹤0.01% | 7533 |
|
|
2022
Q4 | $3.41K | Sell |
4,480
-15,597
| -78% | -$12.3K | ﹤0.01% | 7245 |
|
|
2022
Q3 | $18K | Sell |
20,077
-89,519
| -82% | -$107K | ﹤0.01% | 6827 |
|
|
2022
Q2 | $103K | Buy |
109,596
+89,170
| +437% | +$146K | ﹤0.01% | 6258 |
|
|
2022
Q1 | $43K | Buy |
20,426
+1,617
| +9% | +$4.33K | ﹤0.01% | 6778 |
|
|
2021
Q4 | $168K | Buy |
18,809
+4,212
| +29% | +$55.3K | ﹤0.01% | 6152 |
|
|
2021
Q3 | $242K | Buy |
14,597
+516
| +4% | +$8.91K | ﹤0.01% | 5895 |
|
|
2021
Q2 | $294K | Buy |
14,081
+20
| +0.1% | +$379 | ﹤0.01% | 5824 |
|
|
2021
Q1 | $264K | Buy |
14,061
+2,483
| +21% | +$53.6K | ﹤0.01% | 5495 |
|
|
2020
Q4 | $255K | Buy |
11,578
+5,436
| +89% | +$113K | ﹤0.01% | 5467 |
|
|
2020
Q3 | $128K | Sell |
6,142
-56,874
| -90% | -$1.48M | ﹤0.01% | 5310 |
|
|
2020
Q2 | $2.28M | Buy |
63,016
+59,386
| +1,636% | +$2.49M | ﹤0.01% | 3478 |
|
|
2020
Q1 | $119K | Sell |
3,630
-6,461
| -64% | -$261K | ﹤0.01% | 5112 |
|
|
2019
Q4 | $275K | Buy |
10,091
+9,576
| +1,859% | +$164K | ﹤0.01% | 5267 |
|
|
2019
Q3 | $6K | Buy |
+515
| New | +$4.86K | ﹤0.01% | 6321 |
|
Morgan Stanley's APLT Position: Q1 2026 in Review
Morgan Stanley sold out of Applied Therapeutics (APLT) in Q1 2026, closing a stake of 178,474 shares — an estimated $17.8K sold.
Morgan Stanley first reported a position in APLT in Q3 2019 and held it in 26 quarters. The position peaked at $84.2M in Q3 2024. 0 funds tracked by Wall St. Rank hold APLT as of Q1 2026.
- Morgan Stanley reported no remaining Applied Therapeutics position as of Q1 2026 after selling out during the quarter.
- Morgan Stanley sold 178,474 Applied Therapeutics shares in Q1 2026, an estimated $17.8K.
- Morgan Stanley first reported a position in Applied Therapeutics in Q3 2019 and held it in 26 quarters.
- Morgan Stanley's Applied Therapeutics position peaked at $84.2M in Q3 2024.
- 0 funds tracked by Wall St. Rank held Applied Therapeutics as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.